RT Journal Article
SR Electronic
T1 Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines during the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.27.22273000
DO 10.1101/2022.03.27.22273000
A1 Kiss, Zoltán
A1 Wittmann, István
A1 Polivka, Lőrinc
A1 Surján, György
A1 Surján, Orsolya
A1 Barcza, Zsófia
A1 Molnár, Gergő Attila
A1 Nagy, Dávid
A1 Müller, Veronika
A1 Bogos, Krisztina
A1 Nagy, Péter
A1 Kenessey, István
A1 Wéber, András
A1 Pálosi, Mihály
A1 Szlávik, János
A1 Schaff, Zsuzsa
A1 Szekanecz, Zoltán
A1 Müller, Cecília
A1 Kásler, Miklós
A1 Vokó, Zoltán
YR 2022
UL http://medrxiv.org/content/early/2022/03/30/2022.03.27.22273000.abstract
AB Background In Hungary, the pandemic waves in late 2021 and early 2022 were dominated by the Delta and Omicron SARS-CoV-2 variants, respectively. Booster vaccines were offered with one or two doses for the vulnerable population during these periods.Methods and Findings The nationwide HUN-VE 2 study examined the effectiveness of primary immunization, single booster, and double booster vaccination in the prevention of Covid-19 related mortality during the Delta and Omicron waves, compared to an unvaccinated control population without prior SARS-CoV-2 infection during the same study periods.The risk of Covid-19 related death was 55% lower during the Omicron vs. Delta wave in the whole study population (n=9,569,648 and n=9,581,927, respectively; rate ratio [RR]: 0.45, 95% confidence interval [CI]: 0.44–0.48). During the Delta wave, the risk of Covid-19 related death was 74% lower in the primary immunized population (RR: 0.26; 95% CI: 0.25–0.28) and 96% lower in the booster immunized population (RR: 0.04; 95% CI: 0.04–0.05), vs. the unvaccinated control group. During the Omicron wave, the risk of Covid-19 related death was 40% lower in the primary immunized population (RR: 0.60; 95% CI: 0.55–0.65) and 82% lower in the booster immunized population (RR: 0.18; 95% CI: 0.16–0.2) vs. the unvaccinated control group. The double booster immunized population had a 93% lower risk of Covid-19 related death compared to those with only one booster dose (RR: 0.07; 95% CI. 0.01–0.46). The benefit of the second booster was slightly more pronounced in older age groups.Conclusions The HUN-VE 2 study demonstrated the significantly lower risk of Covid-19 related mortality associated with the Omicron vs. Delta variant and confirmed the benefit of single and double booster vaccination against Covid-19 related death. Furthermore, the results showed the additional benefit of a second booster dose in terms of SARS-CoV-2 infection and Covid-19 related mortality.Competing Interest StatementZsofia Barcza of Syntesia Medical Communications Ltd. received payment for medical writing support from the National Public Health Center of Hungary. Zoltan Kiss is employed by MSD Pharma Hungary Ltd., too. However, this provides no relevant conflict of interest for the current research. At the time the study was performed, M.K served as the minister of human resources. The ministry includes the secretariat for health.Funding StatementThe Center for Health Technology Assessment of the Semmelweis University participated in the project on a contractual basis made with the Ministry of Human Resources of Hungary and received funding. Zsofia Barcza of Syntesia Medical Communications Ltd. received payment for medical writing support from the National Public Health Center of Hungary.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Central Ethical Committee of Hungary (OGYEI/10296-1/2022 and IV/1722- 1/2022/EKU) and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors